# De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast

> **NCT07748260** · PHASE3 · NOT_YET_RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 592 (estimated)

## Conditions studied

- HER2-positive Breast Cancer

## Interventions

- **DRUG:** THP×4 Q3W (n=296) (Investigator-selected taxane* + Trastuzumab IV 6 mg/kg, loading dose 8 mg/kg + Pertuzumab IV 420 mg, loading dose 840mg)
- **DRUG:** THP×6 Q3W (n=296) (Investigator-selected taxane* + Trastuzumab IV 6 mg/kg, loading dose 8 mg/kg + Pertuzumab IV 420 mg, loading dose 840mg)

## Key facts

- **NCT ID:** NCT07748260
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-09-01
- **Primary completion:** 2031-07-01
- **Final completion:** 2031-07-01
- **Target enrollment:** 592 (ESTIMATED)
- **Last updated:** 2026-08-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07748260

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07748260, "De-escalation Neoadjuvant Therapy for Intermediate Risk HER2-positive Early Breast". Retrieved via MORVS 2026-10-21 from https://api.morvs.ai/clinical/NCT07748260. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*